Elypta has announced the launch of its second clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED).
This study, LEVANTIS-0093A (LEV93A), aims to detect any-type cancer in adults at high risk of developing cancer due to significant smoking history.
Elypta will analyze blood samples prospectively collected within the Yorkshire Lung Screening Trial Biomarker sub-study and corresponding participant data prospectively collected within the Yorkshire Lung Screening Trial and the Yorkshire Kidney Screening Trial, all of which are sponsored by the University of Leeds and funded by Yorkshire Cancer Research, in collaboration with the University of Manchester, the University of Leeds, and the Leeds Teaching Hospitals NHS Trust.
LEV93A, sponsored by Elypta, builds upon proof-of-concept data shared at the American Society of Clinical Oncology (ASCO) conference in June 2021 which indicated that GAGomes could detect one third of all stage I cancers across 14 types, including lung and kidney cancer. Elypta’s liquid biopsy exceed the performance of other proposed approaches that use biomarkers based on circulating tumor DNA, which have been shown to perform particularly poorly in kidney cancer despite the high prevalence of this lethal disease among high-risk adults.
LEV93A is the second study in MCED launched by Elypta, following the already initiated LEVANTIS-0087A study (NCT05235009), where the aim is to detect any-type cancer in adults who show no symptoms or have any recent history of cancer.
Photo of Karl Bergman and Francesco Gatto: Elicera